rs104894849
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_000169.3(GLA):c.1095T>G(p.Tyr365*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000169.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 24
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 24
ClinVar
Submissions by phenotype
GLA-related disorder Pathogenic:1
The GLA c.1095T>G variant is predicted to result in premature protein termination (p.Tyr365*). This variant was reported in an individual with Fabry disease (Sakuraba et al 2018. PubMed ID: 30386727). Another DNA variant leading to the same protein truncation (c.1095T>A, p.Tyr365*) was reported in a family with Fabry disease (Miyamura et al. 1996. PubMed ID: 8878432). In a heterozygote individual in this family, lymphocyte alpha-Gal A activity was approximately 30% of the normal control and severe clinical symptoms were apparent. Functional studies support pathogenicity and suggest a dominant negative effect and the importance of the C terminus for protein activity (Miyamura et al. 1996. PubMed ID: 8878432). Although this variant occurs in the last exon and may not succumb to the nonsense mediated decay, it is shortening the protein product by 65 amino acid residues and many pathogenic GLA mutations are reported downstream of this variant. This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Nonsense variants in GLA gene are expected to be pathogenic. This variant is interpreted as pathogenic. -
Cardiovascular phenotype Pathogenic:1
The p.Y365* pathogenic mutation (also known as c.1095T>G), located in coding exon 7 of the GLA gene, results from a T to G substitution at nucleotide position 1095. This changes the amino acid from a tyrosine to a stop codon within coding exon 7. This alteration occurs at the 3' terminus of theGLA gene, is not expected to trigger nonsense-mediated mRNA decay, and impacts the last 15% of the protein. However, premature stop codons are typically deleterious in nature and the impacted region is critical for protein function (Ambry internal data). This variant has been detected in individuals with features consistent with Fabry disease, including a hemizygous male reported to have classic Fabry disease; however, details were limited (Sakuraba H et al. Mol Genet Metab Rep, 2018 Dec;17:73-79; Kobayashi M et al. J Hum Genet, 2019 Jul;64:695-699; Nakano S et al. PLoS One, 2015 Jun;10:e0128351). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.